Molecular basis of acute myeloid leukemia

The advancement of next generation sequencing has identified a spectrum of mutations that contribute to the different types of blood cancers. These mutations can be used for the diagnostic classification and monitoring but in acute myeloid leukemia (AML) and with the exception of acute promyelocytic leukemia (APL), have not resulted in the development of novel targeted therapies. In this keynote presentation, the author will explore the range of mutations and their interactions, examine some of the molecular consequences of these and potentially how the epigenetic therapies may be useful across the different sub-types.

Biography

Ken Mills is the Chair of Experimental Hematology in the Centre for Cancer Research and Cell Biology (CCRCB) in Queen’s University Belfast, UK. He coordinates the activities of the Blood Cancer Research Group with a focus on the molecular aspects of MDS and AML to identify novel therapies. He has published over 135 papers, several book chapters and he is on several Editorial Board and a regular Reviewer for high impact journals and national and international funding bodies.

k.mills@qub.ac.uk

Notes: